Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Receivables (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Receivables for 4 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 9.28% to $21.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.7 million through Dec 2025, up 49.85% year-over-year, with the annual reading at $80.7 million for FY2025, 49.85% up from the prior year.
  • Change in Receivables for Q4 2025 was $21.2 million at Madrigal Pharmaceuticals, down from $34.1 million in the prior quarter.
  • The five-year high for Change in Receivables was $34.1 million in Q3 2025, with the low at $6.9 million in Q2 2024.